We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




HTS Method Based on 3D Tumor Organoid Cultures

By LabMedica International staff writers
Posted on 30 Apr 2018
A drug development team has described a high-throughput screening (HTS)-compatible method – based on three-dimensional (3D) tumor organoids – for evaluating multiple chemical compounds for potential chemotherapeutic drug candidates.

Traditional high-throughput drug screening in cancer research routinely relies on two-dimensional cell models, which inadequately recapitulate the physiologic context of cancer. More...
Three-dimensional cell models are thought to better mimic the complexity of in vivo tumors. Numerous methods to culture three-dimensional organoids have been described, but most are nonhomogeneous and expensive, and hence impractical for high-throughput screening (HTS) purposes.

Investigators at the Scripps Research Institute (Jupiter, FL, USA) sought to develop an improved screening method based on three-dimensional organoids. To this end, the described in the April 19, 2018, online edition of the journal SLAS Discovery an HTS-compatible method that enabled the consistent production of organoids in standard flat-bottom 384- and 1536-well plates by combining the use of a cell-repellent surface with a bio-printing technology incorporating magnetic force.

This novel method combined specialized high-density microtiter plates formulated with an ultra-low attachment surface along with gold nanoparticles (nanoshuttles), which were used to label cancer cells in vitro. Once labeled, a magnet assembled the cells into a three-dimensional spheroid or organoid structure. This three-dimensional structure was retained, and chemical compounds were added to assess their therapeutic efficacy.

The investigators validated this process by evaluating the effects of well-characterized anticancer agents against four patient-derived pancreatic cancer KRAS mutant-associated primary cells, including cancer-associated fibroblasts. The technology was tested for its compatibility with HTS automation by completing a cytotoxicity pilot screen of around 3300 approved drugs.

Data obtained during the study indicated that the technique could be readily applied to support large-scale drug screening relying on clinically relevant, three-dimensional tumor models directly harvested from patients, an important milestone toward personalized medicine.

Related Links:
Scripps Research Institute


New
Gold Member
Collection and Transport System
PurSafe Plus®
Collection and Transport System
PurSafe Plus®
New
Capillary Blood Collection Tube
IMPROMINI M3
New
Blood Glucose Test Strip
AutoSense Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Dormant tumor cells evade imaging tests and may later reactivate to spread metastatic breast cancer (Photo courtesy of David A. Litman/Shutterstock)

MRD Testing Can Identify Breast Cancer Survivors at Higher Risk of Recurrence

Breast cancer survival rates continue to improve, but recurrence remains incurable and affects around 30% of patients. Some subtypes, like triple negative and HER2+, relapse within years, while ER+ cancers... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.